
FDA Approves Zevaskyn for Treating RDEB-Related Blistering Wounds
The U.S. Food and Drug Administration (FDA) has approved prademagene zamikeracel (Zevaskyn) for the treatment of blistering wounds caused by recessive dystrophic epidermolysis bullosa (RDEB) in both adults and children, according to an announcement by …